Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study

This publication has 21 references indexed in Scilit:

• Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study
  Blood, 2017
• Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
  Expert Opinion on Pharmacotherapy, 2017
• From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag
  Therapeutic Advances in Hematology, 2017
• Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
  The Lancet Haematology, 2015
• Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
  Blood, 2014
• The biology of thrombopoietin and thrombopoietin receptor agonists
  International Journal of Hematology, 2013
• Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia
  New England Journal of Medicine, 2012
• Thrombocytopenia in Patients With Myelodysplastic Syndromes
  Seminars in Hematology, 2010
• Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia
  Blood, 2007
• The incidence and impact of thrombocytopenia in myelodysplastic syndromes
  Cancer, 2007